“Rising Adoption of Disease-Modifying Therapies as Standard of Care in Amyloidosis Treatment”
- A significant and accelerating trend in the global biopharmaceutical industry is the expansion of portfolios through strategic licensing agreements. These partnerships enable companies to diversify their product offerings, access innovative therapies, and enter new markets without the need for extensive in-house development.
- For instance, Fresenius Kabi's licensing agreement with SamChunDang Pharm to commercialize an aflibercept biosimilar exemplifies this trend. By securing exclusive rights in the U.S. and several Latin American countries, Fresenius Kabi enhances its ophthalmic treatment portfolio and broadens its market presence
- Such strategic partnerships allow companies to leverage external innovations, reduce time-to-market for new therapies, and meet the growing demand for cost-effective treatment options in various therapeutic areas.
- This trend is particularly pertinent in regions like India, where access to affordable healthcare solutions is crucial, and where partnerships can facilitate the introduction of advanced treatments to underserved populations.
- The demand for advanced Amyloidosis Treatments integrating artificial intelligence and data-driven diagnostic tools is increasing globally, as healthcare providers and patients prioritize precision, early detection, and personalized therapeutic strategies.
